These results demonstrate that the combination treatment of Tra and αPD1 sensitizes mammary tumors with high levels of Smyd3 and Shcbp1 to αPD1 treatment by reversing the oncogenic expression of Smyd3 and Shcbp1 and increasing the functional T-cell populations in mice in general. Here, SHCBP1 is linked to breast cancer.